Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
S. Krueger, J. Papassotiriou, R. Marre, K. Richter, C. Schumann, N. Suttorp, T. Welte (Ulm, Hennigsdorf, Berlin, Hannover, Germany). Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia. Eur Respir J 2007; 30: Suppl. 51, 2922

Member's Comments

No comment yet.

Related content which might interest you: Pro-atrial natriuretic peptide and pro-vasopressin to predict short- and long-term survival in community-acquired pneumonia Source: Annual Congress 2009 - Impact of biomarkers in the management of community-acquired pneumonia Year: 2009 Pro-atrial natriuretic peptide to predict short-term and long-term mortality in community-acquired pneumonia Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 Midregional pro-atrial natriuretic peptide and procalcitonin improve survival prediction in VAP Source: Eur Respir J 2011; 37: 595-603 Year: 2011 Influence of antibiotic pre-treatment on pro-atrial natriuretic peptide in community-acquired pneumonia Source: Annual Congress 2008 - Diagnostic tests in lower respiratory tract infections Year: 2008 Pro-adrenomedullin, pro-atrial natriuretic peptide and procalcitonin levels at admission in patients with community-acquired pneumonia and its correlation with risk scores Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 Mid-regional pro-atrial natriuretic peptide and copeptin as indicators of disease severity and therapy response in CTEPH Source: ERJ Open Res, 6 (4) 00356-2020; 10.1183/23120541.00356-2020 Year: 2020 Levels of procalcitonin, neopterin, C-reactive protein and pro-atrial natriuretic peptide in patients with community-acquired pneumonia and its kinetic according to the severity and the development of complications Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections Year: 2010 Diagnostic value of N-terminal pro-brain natriuretic peptide in patients with COPD with chronic hypoxemic respiratory failure. Source: Virtual Congress 2020 – COPD and the impact of comorbidities Year: 2020 The role of N-terminal pro B-type natriuretic peptide in predicting mortality of community acquired pneumonia Source: International Congress 2019 – Pneumonia in 2019: antimicrobial resistance, cardiovascular complications and diagnosis Year: 2019 Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology Source: Eur Respir J 2012; 39: 1144-1155 Year: 2012 Brain natriuretic peptide (BNP) determination in patients hospitalized for COPD exacerbation Source: Annual Congress 2008 - Biomarkers and disease assessment in COPD Year: 2008 The use of plasma n-terminal pro B-type natriuretic peptide (proBNP) concentrations in differential diagnosis of comorbidity pulmonary patients Source: Annual Congress 2011 - Acute respiratory failure Year: 2011 Brain natriuretic peptide (BNP) levels during acute exacerbations of COPD – a novel biomarker Source: Annual Congress 2008 - Mechanisms of respiratory infections: interaction between the pathogen and the host Year: 2008 MR-proANP and prognosis of ventilator-associated pneumonia Source: Annual Congress 2009 - Ventilator-associated pneumonia, severe community-acquired pneumonia and healthcare associated pneumonia Year: 2009 N-terminal-pro-B-type natriuretic peptide (NT-proBNP) in patient with acute exacerbations (AE) of COPD Source: Annual Congress 2008 - Biomarkers and disease assessment in COPD Year: 2008 B-type natriuretic peptide (BNP) in COPD patients with acute respiratory failure (ARF) Source: Annual Congress 2010 - COPD: cardiovascular comorbidities Year: 2010 The prognostic value of repeated measurements of N-terminal pro-B-type natriuretic peptide in patients with pulmonary hypertension Source: Annual Congress 2010 - Pulmonary circulation: clinical aspects Year: 2010 Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism Source: Eur Respir J 2014; 43: 1669-1677 Year: 2014 The incidence and significance of elevated B-type natriuretic peptide levels in patients hospitalized with apparent respiratory diseases Source: Eur Respir J 2004; 24: Suppl. 48, 279s Year: 2004 Comparison of brain natriuretic peptide to n-terminal pro brain natriuretic peptide in idiopathic interstitial pneumonia Source: Annual Congress 2009 - Pathogenesis of pulmonary fibrosis Year: 2009